BioSpace News Archive

Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

StatLab Medical Products (“StatLab”), a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced the acquisition of Poly Scientific R&D (“Poly Scientific”), a well-known U.S. manufacturer and supplier of high-quality pathology stains, tissue controls, reagents and paraffin for anatomic pathology laboratories.

BD, a leading global medical technology company, was named to Fortune’s 2024 list of America’s Most Innovative Companies.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D. has been added to the Board of Directors.

The Merck Foundation, a private charitable organization funded by Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has made an $11 million, six-year (2023 - 2028) commitment to University of New Mexico Health (UNM Health) in support of its new initiative to bring high-quality care to an estimated 11 million people living with cancer in underserved communities throughout India, Indonesia, Malaysia and Vietnam.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biotechnology company developing novel

Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus’s supplemental Biologics License Application

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field